


JC07 Rec'd PCT/PTO 14 DEC 2001

Certificate of Mailing		
Date of Deposit <u>December 14, 2001</u>		Label Number: <u>EV 040971471 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.		
Guy E. Beardsley Printed name of person mailing correspondence		<i>Guy Beardsley</i> Signature of person mailing correspondence
Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket Number: 50062/006001
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application Number: <b>10/018235</b>
INTERNATIONAL APPLICATION NUMBER	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/FR00/01679	June 16, 2000	June 16, 1999
TITLE OF INVENTION:	NEUROPROTECTIVE AND RETINOPROTECTIVE OPTHAMOLOGIC DRUGS	
APPLICANTS FOR DO/EO/US:	Raouf Rekik, Elyes ben Mohamed Raouf Rekik	
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.	
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.	
3.	<input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. § 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(1).	
4.	<input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.	
5.	A copy of the International Application as filed (35 U.S.C. § 371(c)(2)). <input checked="" type="checkbox"/> a. is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. has been transmitted by the International Bureau. <input type="checkbox"/> c. is not required, as the application was filed with the United States Receiving Office (RO/US).	
6.	<input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. § 371(c)(2)).	
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)). <input type="checkbox"/> a. are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. have been transmitted by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> d. have not been made and will not be made.	
8.	<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).	
9.	<input checked="" type="checkbox"/> An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)).	
10.	<input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371(c)(5)).	
11.	<input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98.	
12.	<input type="checkbox"/> An assignment for recording. A separate cover sheet in compliance with 37 §§ 3.28 and 3.31 is included.	
13.	<input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.	
14.	<input type="checkbox"/> A substitute specification.	
15.	<input type="checkbox"/> A change of power of attorney and/or address letter.	
16.	<input type="checkbox"/> Other items or information:	

17.	<input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 C.F.R. § 1.492(A)(1)-(5)): Neither international preliminary examination fee (37 C.F.R. § 1.482) nor international search fee (37 C.F.R. § 1.455(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 1040.00 International preliminary examination fee (37 C.F.R. § 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 890.00 International preliminary examination fee (37 C.F.R. § 1.482) not paid to USPTO but international search fee (37 C.F.R. § 1.445(a)(2)) paid to USPTO \$ 740.00 International preliminary examination fee (37 C.F.R. § 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1) - (4) \$ 710.00 International preliminary examination fee paid to USPTO (37 C.F.R. § 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00			\$890.00
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$890.00	
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).			\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	52 - 20 =	32	x \$18	
Independent claims	1 - 3 =	0	x \$84	
Multiple dependent claims (if applicable)			+ \$280	
TOTAL OF ABOVE CALCULATIONS =			\$ 1746.00	
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status under 37 C.F.R. § 1.27			\$873.00	
SUBTOTAL =			\$ 873.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).			+	
TOTAL NATIONAL FEE =			\$	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property.			+	
TOTAL FEES ENCLOSED =			\$873.00	
			Amount to be refunded	
			\$	
			charged	
			\$	
<input checked="" type="checkbox"/> a. A check in the amount of \$ 873.00 to cover the above fees is enclosed. <input type="checkbox"/> b. Please charge my Deposit Account No. 03-2095 in the amount of \$ [**,**] to cover the above fees. <input checked="" type="checkbox"/> c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095.				
NOTE: Where an appropriate time limit under 37 C.F.R. §§ 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO: Kristina Bieker-Brady, Ph.D. Clark & Elbing LLP 176 Federal Street Boston, MA 02110-2214 Telephone: 617-428-0200 Facsimile: 617-428-7045 Customer No.: 21559		 Signature Kristina Bieker-Brady, Ph.D. Reg No. 39,109		

V:\PCT Forms\PTO 1390 National Phase Transmittal.wpd

V:\PCT Forms\PTO 1390 National Phase Transmittal.wpd

Revised: 17 March 2000



5310  
5000

1. 13 5000 RECEIVED PCT/PTO 513 MAR 2002

#4

P C I

PATENT

ATTORNEY DOCKET NO. 50062/006001

Certificate of Mailing: Date of Deposit: 3/4/02

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Mary Jane DiPalma Mary Jane DiPalma  
Printed name of person mailing correspondence Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Raouf Rekik et al. Art Unit:  
Serial No.: 10/018,235 Examiner:  
Filed: December 14, 2001 Customer No.: 21559  
Title: NEUROPROTECTIVE AND RETINOPROTECTIVE  
OPHTHAMOLOGIC DRUGS

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination on the merits, please amend the above-captioned application as follows:

In the Specification:

At page 6, please replace paragraph 4 with the following new paragraph:

The invention also concerns pharmaceutical compositions in which the active principles described above are associated with pharmaceutically acceptable vehicles allowing their administration in different forms, in particular: oral forms, parenteral forms, intravenous forms, intramuscular and transdermal forms, and topical forms, in particular as eye or ophthalmic solutions.

At page 7, please replace paragraph 1 with the following new paragraph:

There is clear preference for topical forms of administration, in particular for eye or ophthalmic solutions. These have proven to be particularly effective. Eye solutions actually fill a gap in the treatment of ophthalmologic diseases that involve a vascular factor and which have not been able to be effectively treated until now.

In the claims:

Please cancel claims 1-14 without prejudice or disclaimer of the subject matter contained therein.

Please add the following new claims:

--15. (New) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:

administering a drug comprising an inhibitor of the enzyme that converts angiotensin I to angiotensin II, wherein said drug maintains or improves visual acuity and the field of vision.--

--16. (New) The method according to claim 15, wherein said inhibitor of the enzyme that converts angiotensin I to angiotensin II is an ophthalmic neuro-protector and/or a retinoprotector.--

--17. (New) The method according to claim 15, wherein said inhibitor has:

an equilibrium inhibition constant  $K_i$  that governs the *in vitro* inhibition of rabbit converting enzyme by the inhibitor, wherein the constant is lower than that of enalaprilat (50 pmol/l); and

a constant  $k_4$  for the reversible isomerization of the enzyme-inhibitor complex formed, wherein said constant  $k_4$  is lower than that of the complex formed by enalaprilat and the converting enzyme ( $1.1 \times 10^{-4}$ ) in a medium of 50 mM/l Hepes, 300 mmol/l NaCl, 1 micromol/L  $ZnCl_2$ , pH 7.5.--

--18. (New) The method according to claim 15, wherein vasodilatory activity of the inhibitor is present in the arteries and veins.--

--19. (New) The method according to claim 15, wherein said drug comprising said inhibitor is more lipophilic than enalaprilat.--

--20. (New) The method according to claim 15, wherein said drug comprising said inhibitor is selected from the group of: ramipril, ramiprilat, a pharmaceutically acceptable salt of ramipril, a pharmaceutically acceptable salt of ramiprilat and derivatives thereof, wherein said derivatives can liberate ramiprilat into said patient.--

--21. (New) The method according to claim 15, wherein said drug comprising said inhibitor is administered orally.--

--22. (New) The method according to claim 21, wherein said inhibitor in said drug is administered at a dose of 0.5 to 5 mg/day.--

--23. (New) The method according to claim 21, wherein said inhibitor in said drug is administered at a dose of 1 to 2 mg/day.--

--24. (New) The method according to claim 21, wherein said inhibitor in said drug is administered at a dose of 1.25 mg/day.--

--25. (New) The method according to claim 15, wherein said drug comprising said inhibitor is administered parenterally.--

--26. (New) The method according to claim 25, wherein said drug comprising said inhibitor is administered intravenously or intramuscularly or transdermically or topically.--

--27. (New) The method according to claim 26, wherein said drug comprising said inhibitor is administered topically to the eye.--

--28. (New) The method according to claim 27, wherein said drug is administered as an ophthalmic solution.--

--29. (New) The method according to claim 15, wherein said patient has a degenerating chorioretinopathy or has an optic neuropathy or has both a degenerating chorioretinopathy and an optic neuropathy.--

--30. (New) The method according to claim 15, wherein said patient has a glaucomatous neuropathy.--

--31. (New) The method according to claim 15, wherein said patient has a degenerative chorioretinopathy in severe myopia.--

--32. (New) The method according to claim 15, wherein said patient has age-related macular degeneration with or without sub-retinal neovessels.--

--33. (New) The method according to claim 15, wherein said patient has a central serous chorioretinopathy or a chronic central serous chorioretinopathy.--

--34. (New) The method according to claim 15, wherein said patient has a hereditary dystrophy of the retina.--

--35. (New) The method according to claim 34, wherein said hereditary dystrophy of the retina is a retinitis pigmentosa.--

--36. (New) The method according to claim 15, wherein said patient has a retinal venous occlusion.--

--37. (New) The method according to claim 15, wherein said patient is aged.--

--38. (New) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:

administering an ophthalmic drug comprising as an active ingredient ramipril or ramiprilat.--

#### REMARKS

Entry of the foregoing and favorable examination of the subject matter of the newly submitted claims is respectfully requested.

By the present amendment, Applicants have canceled original claims 1-14 and has added new claims 15-38. The present claims of record are being submitted to provide the Examiner with claims that are in proper U.S. format and hence easier to examine. Applicants submit that no new matter has been added via this amendment and support for these new claims appears throughout the specification as filed and in the previous claims of record.

The specification has been amended to modify the term "eye lotion" at pages 6 and 7 of the specification to eye or ophthalmic solution. It is clear that the word lotion refers to a liquid that is put on the skin and not in the eyes. However, the present invention



relates to treating the eyes and not the skin. Therefore, the word was mistranslated into English from the French term since the French term has several meanings. Thus, Applicants submit that no new matter has been added due to this amendment to the specification.


Applicants respectfully request entry of these amendments.

From the foregoing, favorable action in the form of a Notice of Allowance is respectfully requested and such action is earnestly solicited.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: March 3, 2002

  
\_\_\_\_\_  
Kristina Bicker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

\\Clark-w2k1\documents\50062\50062 006001 Preliminary amendment wpd



21559

PATENT TRADEMARK OFFICE

Version to Show Changes Made

At page 6, paragraph 4.

The invention also concerns pharmaceutical compositions in which the active principles described above are associated with pharmaceutically acceptable vehicles allowing their administration in different forms, in particular: oral forms, parenteral forms, intravenous forms, intramuscular and transdermal forms, and topical forms, in particular as eye [lotions] or ophthalmic solutions.

At page 7, paragraph 1.

There is clear preference for topical forms of administration, in particular for eye [lotions] or ophthalmic solutions. These have proven to be particularly effective. Eye [lotions] solutions actually fill a gap in the treatment of ophthalmologic diseases that involve a vascular factor and which have not been able to be effectively treated until now.

Pending Claims

--15. (New) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:  
administering a drug comprising an inhibitor of the enzyme that converts angiotensin I to angiotensin II, wherein said drug maintains or improves visual acuity and the field of vision.--

--16. (New) The method according to claim 15, wherein said inhibitor of the enzyme that converts angiotensin I to angiotensin II is an ophthalmic neuro-protector and/or a retinoprotector.--

--17. (New) The method according to claim 15, wherein said inhibitor has:  
an equilibrium inhibition constant  $K_i$  that governs the *in vitro* inhibition of rabbit converting enzyme by the inhibitor, wherein the constant is lower than that of enalaprilat (50 pmol/l); and  
a constant  $k_4$  for the reversible isomerization of the enzyme-inhibitor complex formed, wherein said constant  $k_4$  is lower than that of the complex formed by enalaprilat and the converting enzyme ( $1.1 \times 10^{-4}$ ) in a medium of 50 mM/l Hepes, 300 mmol/l NaCl, 1 micromol/L  $ZnCl_2$ , pH 7.5.--

--18. (New) The method according to claim 15, wherein vasodilatory activity of the inhibitor is present in the arteries and veins.--

--19. (New) The method according to claim 15, wherein said drug comprising said inhibitor is more lipophilic than enalaprilat.--

--20. (New) The method according to claim 15, wherein said drug comprising said inhibitor is selected from the group of: ramipril, ramiprilat, a pharmaceutically acceptable salt of ramipril, a pharmaceutically acceptable salt of ramiprilat and derivatives thereof, wherein said derivatives can liberate ramiprilat into said patient.--

--21. (New) The method according to claim 15, wherein said drug comprising said inhibitor is administered orally.--

--22. (New) The method according to claim 21, wherein said inhibitor in said drug is administered at a dose of 0.5 to 5 mg/day.--

--23. (New) The method according to claim 21, wherein said inhibitor in said drug is administered at a dose of 1 to 2 mg/day.--

--24. (New) The method according to claim 21, wherein said inhibitor in said drug is administered at a dose of 1.25 mg/day.--

--25. (New) The method according to claim 15, wherein said drug comprising said inhibitor is administered parenterally.--

--26. (New) The method according to claim 25, wherein said drug comprising said inhibitor is administered intravenously or intramuscularly or transdermally or topically.--

--27. (New) The method according to claim 26, wherein said drug comprising said inhibitor is administered topically to the eye.--

--28. (New) The method according to claim 27, wherein said drug is administered as an ophthalmic solution.--

--29. (New) The method according to claim 15, wherein said patient has a degenerating chorioretinopathy or has an optic neuropathy or has both a degenerating chorioretinopathy and an optic neuropathy.--

--30. (New) The method according to claim 15, wherein said patient has a glaucomatous neuropathy.--

--31. (New) The method according to claim 15, wherein said patient has a degenerative chorioretinopathy in severe myopia.--

--32. (New) The method according to claim 15, wherein said patient has age-related macular degeneration with or without sub-retinal neovessels.--

--33. (New) The method according to claim 15, wherein said patient has a central serous chorioretinopathy or a chronic central serous chorioretinopathy.--

--34. (New) The method according to claim 15, wherein said patient has a hereditary dystrophy of the retina.

--35. (New) The method according to claim 34, wherein said hereditary dystrophy of the retina is a retinitis pigmentosa.--

--36. (New) The method according to claim 15, wherein said patient has a retinal venous occlusion.--

--37. (New) The method according to claim 15, wherein said patient is aged.--

--38. (New) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:

administering an ophthalmic drug comprising as an active ingredient ramipril or ramiprilat.--



500

10018235-052202  
JG18 Rec'd PCT/PTO 22 APR 2002 #5

PATENT  
ATTORNEY DOCKET NO. 50062/006001

Certificate of Mailing: Date of Deposit: <u>April 12, 2002</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as <b>first class mail</b> with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Mary Jane DiPalma</u> Printed name of person mailing correspondence	<u>Mary Jane DiPalma</u> Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Raouf Rekik et al.	Art Unit:	
Serial No.:	10/018,235	Examiner:	
Filed:	December 14, 2001	Customer No.:	21559
Title:	NEUROPROTECTIVE AND RETINOPROTECTIVE OPTHAMOLOGIC DRUGS		

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination kindly amend the above-referenced application as follows:

In the Specification:

At page 1, after the title please insert the following paragraph:

This application claims the benefit of foreign priority under 35 U.S.C. § 119 to applications FR 99/15359, filed December 16, 1999, and SN 99 122, filed June 16, 1999. This application is a 371 of PCT/FR00/01679, filed June 16, 1999.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

April 12, 2002

Kristina Bieker-Brady  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADE MARK OFFICE


## VERIFICATION OF TRANSLATION

I, Dr Lesley Margaret Stone, B.Sc., Ph.D., D.M.S., of Silver Creek, Lhergy Cripperty, Union Mills, Isle of Man, IM4 4NJ, British Isles, do hereby declare that I am conversant with the English and French languages and that I am a competent translator thereof;

I verify that the attached English translation of International Patent Application Number PCT/FR00/01679 filed on 16<sup>th</sup> June 2000 is a true and correct translation made by me of the attached document in the French language;

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 19<sup>th</sup> November 2001

A handwritten signature in black ink, appearing to read 'Lesley Stone', is written over a horizontal line.

**NEUROPROTECTIVE AND RETINOPROTECTIVE OPHTHALMOLOGIC DRUGS**

The invention relates to the production of neuroprotective and retinoprotective drugs for maintaining or improving visual function (visual acuity and field of vision). More particularly, it relates to such drugs for the treatment of ophtalmologic disorders involving chorioretinal deterioration or deterioration of the optic nerve or both at once, with a resultant progressive loss of vision (visual acuity and field of vision).

Such effects on vision are observed in particular in glaucoma, conventionally associated with the notion of ocular hypertension.

Clearly, ocular hypertension can have a deleterious effect on the optic nerve. However, experience has shown that such a result of intraocular pressure is not necessarily the cause of glaucoma, since it has been observed that many patients suffer from intraocular hypertension without running any risk of degradation of the optic nerve or of a progressive reduction in their field of vision. In contrast, attacks of a glaucomatous nature on the optic nerve have been observed in other categories of patients, associated with a progressive loss of field of vision, with no concomitant increase in intraocular pressure.

Of course, some prior art documents have already evaluated the presumed action of angiotensin converting enzyme inhibitors (CEI) on ocular pressure (IOP). They did not reveal their importance in improving vision. Further, the recent article by M. Détry Morel published in the review J. Fr. Opthamlol., 1999; 22,1, 122-134 (1999), entitled "Perspectives dans le traitement médical de la neuropathie glaucomateuse -Bases de la neuroprotection" [Perspectives in the medical treatment of glaucomatous neuropathy - Bases for neuroprotection], which reviews the current state of the development of drugs for the medical treatment of glaucomatous neuropathies, makes reference to the envisaged use of some vasoactive drugs using certain angiotensin converting enzyme inhibitors for overcoming the reduction in ocular blood flow that can be observed in patients with certain forms of glaucoma. However, according to Détry-Morel, while certain of those drugs are capable of inducing an increase in ocular blood flow,



great caution has to be exercised since it is not known whether the increase is accompanied by a beneficial effect for patients or, in contrast, consists solely of a secondary effect. Détry-Morel particularly mentions the possibility that the increase, normally coped with by healthy tissue, may have disastrous consequences in tissue where the vascular bed is initially in a precarious state. Finally, Détry-Morel makes no observations regarding interruption of the optic nerve deterioration process or of the progressive loss of field of vision, and also no mention of an improvement in field of vision for any of the treatments reviewed.

The invention aims to provide drugs intended for the treatment of ophtalmologic diseases that can improve visual function, in particular field of vision and visual acuity, in patients suffering from neuropathies such as glaucoma, but also other chorioretinal disorders or deteriorations of the optic nerve that may involve a vascular factor. Examples of these diseases that can be mentioned are:

- (1) glaucomatous neuropathies, including glaucoma itself, of course;
- (2) degenerative chorioretinopathy in severe myopia;
- (3) age-related macular degeneration (ARMD);
- (4) diffuse retinal epitheliopathies (DR) and central serous retinopathy (CSCR);
- (5) hereditary dystrophies of the retina;
- (6) retinal venous occlusions.

The invention is founded on the discovery that when used to treat patients, certain angiotensin I to angiotensin II converting enzyme inhibitors (CEI) cause not only an interruption, which until now has not been observed in patients treated for diseases of the types mentioned above, but moreover at least partial inversion of the visual function degradation process, with an improvement in visual acuity and field of vision.

However, the drugs of the invention are not limited to applications of the type mentioned above. They can usefully be employed to prevent or slow down or even stop “natural”

reductions in visual acuity, field of vision or both at once. In particular, they have a happy application in preventing and even reversing visual decline in old age.


Mean retinal sensitivity reduces linearly with age. This decline starts very early on, from 20 years of age and accelerates after the age of 60. In particular, the mean sensitivity (MS) expressed in decibels (dB) obeys the following equation, according to Jaffe:

$$MS (dB) = 28.8 - 0.074 \times \text{age}.$$


This is used by the automatic perimeter (octopus <sup>TM</sup>) to calculate age-corrected sensitivity. In the central 30°, retinal sensitivity not only declines faster at the periphery than at the centre, but also more at the upper periphery than in the other quadrants.

Automated perimetry has shown that administering a suitable CEI, in particular ramipril, to normal subjects improves mean sensitivity by more than 1 to 2 dB. The mean sensitivity is that considered to be normal by the software; it includes an evaluation of "normal" losses which is a function of the age of the subjects for whom any losses that are supplemental to the mean sensitivity are to be determined if they suffer from one of the diseases mentioned above, for example.

Currently, the most effective molecule is constituted by ramipril, which has the following formula:



or ramiprilat, which results from de-esterification of ramipril, which has the following formula:



Doubtless, such drugs intervene in the CEI action mechanism, in that they act by preventing the transformation of angiotensin I to angiotensin II (vasoconstrictor) and the degradation of bradykinins (vasodilators). These CEIs thus cause vasodilation, which is exerted on arteries and on veins. Thus, they are mixed vasodilators. It should be remembered that the mechanism for the formation of the bond that can be formed between the inhibitor and the enzyme normally occurs in two phases, the first consisting of the formation of an inhibitor-enzyme complex by a competitive bond, which involves a reaction governed by a constant  $K_i$ , and the second, consisting of a slow isomerisation of the inhibitor-enzyme complex, itself also governed by a reversible rate constant for this reaction,  $k_4$ .

An explanation of the above concepts can be found in the publication by D. Vasmant and N. Bender entitled "Renin-angiotensin and ramipril system, a novel converting enzyme inhibitor" in the Journal of Cardiovascular Pathology 14 (suppl. 4) (1989): S49-S56, Raven Press, which itself refers to earlier publications by Bünning P "Inhibition of angiotensin converting enzyme by 2-(N-((S)-1-carboxy-3-phenoxy)-L-alanyl)-(1S,3S,5S)-2-azabicyclo(3.3.0)octane-3-carboxylic acid (HOE A98) diacid. Comparison with captopril and enalaprilat" in Drug Research 1984; 34: 1406-1410, and the doctoral thesis by Shapiro R. (Ph.D. Thesis, Harvard University Cambridge, MA, 1983 "Activation and inactivation of rabbit pulmonary angiotensin converting enzyme".

Ramipril and ramiprilat are of particular importance. Ramiprilat, which results from the de-esterification of ramipril, can form more stable complexes with angiotensin converting enzyme than other inhibitors. In particular, the half-life of such complexes is of the order of 12 to 17 hours. They are also distinguished from many other angiotensin converting enzyme inhibitors by their lipophilic nature and by the greater stability of the enzyme-inhibitor couples formed. All of those properties contribute to the manifestation of effects that can be obtained at very small doses, as will be shown in the examples below.

Effective doses for producing effects in the ophtalmologic field are desirably lower than doses that would induce general arterial hypotension in a subject with normal pressure. Clearly, the doses that can be used can be higher in subjects with hypertension, although this is not necessary, since the desired effect is that obtained in the ophtalmologic field.

Clearly, any other CEI with a somewhat lipophilic nature (and, if necessary, retaining a partially hydrophilic nature) can be used instead of ramipril or ramiprilat, that CEI having a high affinity for the converting enzyme and, as a result, allowing the formation of stable enzyme-inhibitor complexes. Complex stability appears to play an important role in the capacity of the drugs in question to exert its visual function improvement action. The invention thus concerns a method of manufacturing a drug for the production of neuroprotective and retinoprotective drugs employing, as the active principle, an angiotensin converting enzyme inhibitor that can form a complex with the angiotensin converting enzyme that is sufficiently stable not only to interrupt the visual function degradation process in patients suffering from the pathologies in question, but also to reverse or regress that process.

In particular, any CEI simultaneously exhibiting the following can be used:

- an equilibrium inhibition constant  $K_i$  that governs the in vitro inhibition of rabbit converting enzyme by the CEI in question, the constant being lower than that of enalaprilat (50 pmol/l); and
- a constant  $k_4$  for the reversible isomerisation of the enzyme-inhibitor complex formed, the constant being lower than that of enalaprilat ( $1.1 \times 10^{-4}$ )(S1) in a medium (50 mM/l Hepes, 300 mmol/l NaCl, 1 micromol/l  $ZnCl_2$ , pH 7.5) using Bünning and Shapiro methods under the conditions described by those authors in the articles identified above.

Advantageously again, the CEIs that can be used in the context of the invention have a lipophilic nature that is greater than that of enalaprilat, for example under conditions using comparative measurements of partition coefficients in an octanol/water medium at an acidic pH.

The most lipophilic nature will be demonstrated by passage of a larger proportion of the CEI of the invention into the octanol phase than for enalaprilat over a substantial range of acidic pHs, in particular in the range pH 2-4.

When used instead of ramipril, enalaprilat exhibits a moderate improvement in visual function in treated patients. However, the effects observed with ramiprilat, in which the constant  $K_i$  is 7 (7 times higher than with enalaprilat) and the constant  $k_4$  is  $1.8 \times 10^{-5}$  (i.e., the complex that ramiprilat forms with the enzyme is six times more stable than that formed by enalaprilat) are incomparably better. It should be remembered that the physico-chemical indications described above originate from the article by Vasmant et al., *loc.cit.*

Similar observations based on real trials have not only been carried out on those with glaucomatous neuropathies, but also on those suffering from all other types of disorders involving a vascular factor.

More particularly, the invention concerns the use of the compounds described above for the manufacture of drugs for use in inducing an improvement in visual acuity and field of vision in treated persons.

The invention also concerns pharmaceutical compositions in which the active principles described above are associated with pharmaceutically acceptable vehicles allowing their administration in different forms, in particular: oral forms, parenteral forms, intravenous forms, intramuscular and transdermal forms, and topical forms, in particular as eye lotions.

While the numerical indications given below should not be considered to be limiting in nature, as those can be left to the clinician and the patient, the following daily doses of active principle – in particular when that active principle is constituted by ramipril or ramiprilat – are effective when administered orally, namely in an amount of 0.5 to 5, preferably 1 to 2 mg/day, for example 1.25 mg/day. Clearly, the dosage can vary from one patient to another and fine tuning can be left to the clinician. These doses may be different when using different drugs. While the following parameter should not be considered to be limiting in nature, it appears that

the degree of stability of the complex formed by the selected CEI with the converting enzyme must also be taken into account when determining the most effective daily doses.

There is a clear preference for topical forms of administration, in particular for eye lotions. These have proved to be particularly effective. Eye lotions actually fill a gap in the treatment of opthalmologic diseases that involve a vascular factor and which have not been able to be effectively treated until now.

In other words, in the preferred forms of the drug according to the inventor, the different CEIs used are associated with pharmaceutical vehicles that allow their clinical application in the form of eye lotions.

The invention will now be illustrated by the following description of clinical examples which, of course, are not limiting in nature. In these examples the active principle, in particular ramipril, was administered continuously in an oral form, in an amount of 1.25 mg per day. Reference is also made to the accompanying Figures 1 to 8, which indicate the results obtained with an automatic parameter (octopus<sup>TM</sup>) and which demonstrate the capacity of the drugs of the invention to cause a substantial improvement in the field of vision of certain of these patients.

Figures 1 and 2 reproduce the fields of vision of the left eye; Figures 3 and 4 reproduce the field of vision of the right eye as perceived by one of the treated patients who suffered from glaucomatous neuropathy, respectively before treatment (Figures 1 and 3) and after treatment, 10 days later (Figures 2 and 4).

Figures 5 and 6 reproduce the fields of vision of the left eye; Figures 7 and 8 reproduce the field of vision of the right eye as perceived by one of the treated patients who suffered from sectorial retinitis pigmentosa, respectively before treatment (Figs 5 and 7) and after treatment, two months later (Figures 6 and 8).

The upper left portion of each of the Figures shows the grey scale (GS); the lower left portion shows the Bebie curve; the upper right portion shows the threshold values (in dB)

measured at set points in the retina; and the lower right portion shows comparative values (in dB).

The grey scale provides an “image” of visual function, point by point, of different regions of the retina; the palest zones correspond to regions in which the visual functions are the least altered; the darkest zones correspond to those that have altered the most. A relative lightening of one of the regions in question after treatment demonstrates a local improvement in visual functions. A reduction in the darkest regions also indicates local visual recovery in regions that have become lighter.

The values that appear in the right hand portions of the figures correspond to the threshold values measured locally at set points in the retina. The increase in these values measured at certain points after treatment demonstrate a local improvement in vision. In contrast, the values that appear in the lower right hand portions of the figures correspond to local loss of vision in the zones concerned of the retina compared with the normal. A reduction in these values, when observed after treatment, is evidence of an improvement in visual function on a local level.

The Bebie curves also provide comparative images of the visual capacity of the subject under examination (lower curves) compared with the curves for normal or quasi-normal subjects (upper curves). An improvement in visual function in a treated patient is demonstrated when the Bebie curve comes close to the curves obtained for normal subjects.

Remarkably, equivalent observations were made in “normal” subjects, in particular ageing subjects, to whom the drug had been administered, these ageing subjects regaining the mean sensitivity they knew when they were much younger.

Further characteristics of the invention will become clear from the following clinical observations that are, of course, provided solely by way of illustration and do not in any way limit the scope of the invention.

## GLAUCOMATOUS NEUROPATHY

The ischemic origin of glaucomatous neuropathy was suspected in the light of angiographic exploration.

Fluorescein angiography showed:

1) Optic papilla:

- either a delay in impregnation of glaucomatous papilla;
- or absolute impregnation defects. These faults correlated with alterations in the field of vision.

2) Choroid:

Fluorescein angiography showed:

- a delay in choroidal filling: in 100% of cases;
- an irregularity in sector filling;
- abnormal visibility of principal choroidal vessels.

3) Retina:

- Longer retinal arterial period.

Patients with known glaucoma presenting with arterial hypertension had an improvement in visual acuity and their field of vision in a very short period, as soon as treatment was commenced. We shall now list the effects obtained:

- Visual acuity: substantial improvement, the most spectacular case being that of a patient whose visual acuity increased from 3/10 to 10/10 (LE) and from 6/10 to 8/10 (RE);
- Field of vision: Studied by Goldmann comparison, and in particular with automated perimetry; the improvement was substantial and spectacular; on average, the loss in mean sensitivity reduced by 30%, which is original and exceptional;
- Ocular tension: Significant reduction, but of an irregular amount.



neuropathy, this disorder appears to consist essentially of an ischemic vascular disease necessitating vascular treatment.

Figures 1 to 4 also demonstrate an improvement in the visual function, in particular under the conditions summarised above. The data given for these Figures also appears in the tables below (the numbers, of course, correspond to those in the figures):

**Table 1**Left eye before treatment

			Normal	Phase 1	Phase 2	Mean
Mean sensitivity	MS			16.9	17.3	16.5
Mean drop	MD	[dB]	-2..2	9.5	9.4	9.9
Loss variance	LV	[dB]	0..6	26.8	29.3	
Corr. Loss variance	CLV	[dB] <sup>2</sup>	0..4			22.4
Short term fluctuation	SF	[dB] <sup>2</sup>	0..2			2.7
Reliability factor	RF	[%]				4.9

**Table 2**Left eye after treatment

			Normal	Phase 1	Phase 2	Mean
Mean sensitivity	MS			20.0	20.0	20.2
Mean drop	MD	[dB]	-2..2	5.7	6.8	6.2
Loss variance	LV	[dB]	0..6	16.8	26.5	
Corr. Loss variance	CLV	[dB] <sup>2</sup>	0..4			13.1
Short term fluctuation	SF	[dB] <sup>2</sup>	0..2			3.0
Reliability factor	RF	[%]				5.0

**Table 3**Right eye before treatment

			Normal	Phase 1	Phase 2	Mean
Mean sensitivity	MS			17.4	17.4	16.9
Mean drop	MD	[dB]	-2..2	9.0	9.3	9.5
Loss variance	LV	[dB]	0..6	28.6	21.0	
Corr. Loss variance	CLV	[dB] <sup>2</sup>	0..4			21.8
Short term fluctuation	SF	[dB] <sup>2</sup>	0..2			3.0
Reliability factor	RF	[%]				2.3

**Table 4**Right eye after treatment

			Normal	Phase 1	Phase 2	Mean
Mean sensitivity	MS			22.2	21.9	21.6
Mean drop	MD	[dB]	-2..2	4.1	4.7	4.8
Loss variance	LV	[dB]	0..6	17.2	10.4	
Corr. Loss variance	CLV	[dB] <sup>2</sup>	0..4			13.1
Short term fluctuation	SF	[dB] <sup>2</sup>	0..2			2.6
Reliability factor	RF	[%]				2.3

The figures show a substantial improvement in visual function; the tables provide a complementary illustration, in particular as regards the mean sensitivity, which increased from 16.5 to 20.2 for the left eye, and from 16.9 to 21.6 for the right eye. Similarly, a substantial regression in mean loss of vision with respect to the normal should be noted: from 9.9 to 6.2 for the left eye and from 9.5 to 4.8 for the right eye.

### **DEGENERATIVE CHORIO-RETINOPATHY IN SEVERE MYOPIA**

The hypothesis that there is a vascular factor in the genesis of choroidal lesions has been advanced because of the presence of vascular lesions in the choroid. Vascular occlusion first affects the choriocapillary, which is atrophic, then involves the medium vessels followed by the large vessels. Atrophy follows, and even disappearance of the choroid predominating at the posterior pole and at least partially conditioning retinal attack, which becomes atrophic. However, the retinal vessels participate in such atrophy. The improvement in corrected visual acuity does not currently appear ever to have been established in severely myopic patients affected by a degenerative chorioretinopathy.

Even in a low dose, ramipril always causes an improvement in corrected visual acuity despite the existence of extremely severe myopic choroidosis. By way of example, visual acuity changed respectively: from simple light perception (LP) to 1/20 for the monophthalmic eye; from 2/10 (RE) 1/10 (LE) to 5/10(RE) and 5/10 (LE); from 1.5/10 to 3/10; from 1/20 (both eyes) to 2/10 (RE) and 1/10 (LE); from 1/10 (RE) and 1/10 (LE) to 6/10 (RE) and 3/10 (LE). Clearly, the term RE used here means "right eye" and the term LE used here means "left eye".

### **AGE-RELATED MACULAR DEGENERATION (ARMD)**

The ischemic nature of ARMD has been evoked on the basis of the following data.

#### **Angiographic data:**

A recent study has shown a reduction in macular choroidal perfusion in 26 out of 100 patients presenting a ARMD.

#### **Histological study:**

This showed:

- a progressive increase in intervascular tissue, which can shrink the lumen of the choriocapillary and associated arterioles;
- a reduction in the number and diameter of choroidal capillaries;
- 5      • a reduction in the number of medium choroidal vessels;
- anomalies, in particular atrophy of the perifoveolar retinal capillary bed; it appears atrophic.

The majority of patients presenting an age-related macular degeneration with or without sub-retinal neovessels treated with ramipril experienced improved visual acuity. By way of  
 10      example, visual acuity changed respectively from 0.16 to 0.3; 0.2 to 0.5; from 0.05 to 0.2 (right eye) and 0.05 to 0.15 (left eye); from 0.2 to 0.4 (right eye) and from 0.5 to 0.8 (left eye); from 0.6 to 1; from 0.4 to 0.6 (right eye) and from 0.2 to 0.5 (left eye).

### **HEREDITARY DYSTROPHY OF THE RETINA AND PIGMENTARY EPITHELIUM**

#### **Retinitis pigmentosa:**

15      This disorder corresponds to a dystrophy in the cones and rods. It is characterized by the appearance of night blindness in infancy or adolescence, a progressive contraction of the peripheral field of vision starting with an equatorial annular scotoma, and results in a substantial loss in visual acuity or even blindness by adulthood.

20      **A vascular component** has been demonstrated in this type of dystrophy. It is shown by clinical, angiographic and histological analysis:

1.      **Clinical:** Reduction in the size of retinal vessels.
2.      **Angiography:**
  - increase in retinal circulation period;
  - dilation of capillaries of the retina and optic papilla;
  - 25      • choroidal circulation delay.
3.      **Histopathology:**

- thickening, with hyalitis, of the retinal vessel walls;
- partial obliteration of choriocapillary, which becomes atrophic.

### **DEVELOPMENT AND PROGNOSIS**

The prognosis is poor. It is marked by a constant progression in the disorder towards  
5 blindness. There is no known treatment.

The existence of this vascular factor has given rise to the idea of testing the drugs of the  
invention in hereditary dystrophies of the retina and the pigmentary epithelium.

Ramipril was used in the following three disorders: retinitis pigmentosa; Stargardt's  
disease, fundus flavimaculatus; adult pseudo-vitelliform dystrophy. In all cases, it caused an  
10 improvement in visual function.

#### **Retinitis pigmentosa**

Three patients were treated with 1.25 mg of ramipril orally and their visual acuity  
improved in the space of two months:

**First patient:** Visual acuity for the right eye changed from doubtful light perception to  
15 1/50 and for the left eye, from 1/50 to 1.6/10.

**Second patient:** Monophthalmic visual acuity changed from 2/10 to 5/10.

**Third patient:** Suffering from sectorial retinitis pigmentosa, his visual acuity changed  
from 1.6 to 6/10 in the right eye and from 1.6 to 4/10 in the left eye. The mean sensitivity for the  
automated optometric field of vision improved from 16.5 to 18 in the right eye and from 16.8 to  
20 19.9 in the left eye.

The electroretinogram was substantially improved, especially in the red and in the left  
eye.

#### **Stargardt's flavimaculatus disease**

One patient was treated; acuity improved from 1/20 to 1/10 in the right eye and from 1/50  
25 to 3/10 in the left eye.

### Pseudovitelliform dystrophy

One patient was tested. Acuity improved in one month from 1.6 to 2/10 in the right eye and from 2/10 to 3/10 in the left eye. The activity of the ramipril in these hereditary dystrophies is unique.

5 Reproductions of the fields of vision for the third patient with sectorial retinitis pigmentosa, respectively before and after two months of treatment, are shown by way of example in Figures 5 and 6 for the left eye, and in Figures 7 and 8 for the right eye.

Figures 5 to 8 also show a substantial improvement in visual function. The data shown in respectively corresponding Tables 5 to 8 provide a supplemental illustration. In particular, the  
 10 mean sensitivity improved from 16.8 to 20.9 for the left eye and from 16.5 to 18.3 for the right eye. Similarly, the average loss of vision with respect to the normal dropped from 10.3 to 6.5 for the left eye and 10.6 to 8.8 for the right eye.

**Table 5**Left eye before treatment

			Normal	Phase 1	Phase 2	Mean
Mean sensitivity	MS			17.3	17.9	16.8
Mean drop	MD	[dB]	-2..2	9.8	9.6	10.3
Loss variance	LV	[dB]	0..6	60.6	52.8	
Corr. Loss variance	CLV	[dB] <sup>2</sup>	0..4			52.5
Short term fluctuation	SF	[dB] <sup>2</sup>	0..2			2.5
Reliability factor	RF	[%]				9.8

**Table 6**Left eye after treatment

			Normal	Phase 1	Phase 2	Mean
Mean sensitivity	MS			21.2	20.8	20.9
Mean drop	MD	[dB]	-2..2	6.2	7.0	6.5
Loss variance	LV	[dB]	0..6	51.8	63.9	
Corr. Loss variance	CLV	[dB] <sup>2</sup>	0..4			48.0
Short term fluctuation	SF	[dB] <sup>2</sup>	0..2			1.9
Reliability factor	RF	[%]				7.9

**Table 7**Right eye before treatment

			Normal	Phase 1	Phase 2	Mean
Mean sensitivity	MS			16.8	16.0	16.5
Mean drop	MD	[dB]	-2..2	10.2	11.5	10.6
Loss variance	LV	[dB]	0..6	70.4	86.9	
Corr. Loss variance	CLV	[dB] <sup>2</sup>	0..4			66.0
Short term fluctuation	SF	[dB] <sup>2</sup>	0..2			2.4
Reliability factor	RF	[%]				12.2

**Table 8**Right eye after treatment

			Normal	Phase 1	Phase 2	Mean
Mean sensitivity	MS			18.4	18.2	18.3
Mean drop	MD	[dB]	-2..2	8.7	9.2	8.8
Loss variance	LV	[dB]	0..6	67.5	79.8	
Corr. Loss variance	CLV	[dB] <sup>2</sup>	0..4			65.6
Short term fluctuation	SF	[dB] <sup>2</sup>	0..2			1.7
Reliability factor	RF	[%]				10.3

## **RETINAL VENOUS OCCLUSIONS**

The syndrome of occlusion of the central vein of the retina or one of its branches corresponds to a slowing down of the circulation to a greater or lesser extent. It does not stop completely.

It is defined by the presence of fundamental symptoms:

- alteration in vision;
- retinal circulatory slowdown;
- venous dilation;
- retinal haemorrhages;
- diffuse retinal oedema;
- cotton-like nodules;
- alteration of capillary bed.

The prognosis for this type of disorder is uncertain. It depends on the clinical form. Complications can aggravate the situation, in particular macular oedema, haemorrhage of the aqueous humour and neovascular glaucoma.

The only known treatment is laser photocoagulation. This treats the complications rather than the occlusion itself.

The majority of patients treated with ramipril improved both on the functional and on the angiographic level.

By way of example, two patients presenting an oedematous and ischemic type venous branch occlusion had improved visual acuity of respectively 2/10 to 8/10 and 6/10 to 10/10 in the space of two months.

By improving the perfusion pressure, ramipril improves blood flow and thus directly treats venous occlusion, which is once again defined as a slowing down of the venous circulation.



**RETINAL EPITHELIOPATHY AND CENTRAL SEROUS CHORIORETINOPATHY**  
**(CSCR)**

Vascular alterations have been proved. Indocyanine green angiography has shown these diffuse choroidal vascular alterations with choroidal hyperpermeability.

5        This latter causes serous detachment of the pigmentary epithelium. The pressure exerted on the pigmentary epithelium produces a leak that mechanically causes macular retinal serous detachment.

10        In the space of a few days to a few weeks, the use of ramipril has caused a reduction in the blister and thus application of the retinal neuroepithelium: this leads to an improvement in visual acuity and in the central field of vision.

For ramipril and ramiprilat, the improvement in field of vision is brought about by doses that do not cause arterial hypertension in the healthy subject.

15        Taking the vasodilatory action of ramipril and ramiprilat into account and because of the responsibility of the vascular factor in the development of the six pathologies, namely glaucomatous neuropathy, degenerative chorioretinopathy of severe myopia, ARMD, central serous chorioretinopathy, retinal venous occlusion and hereditary dystrophies of the retina, it can be seen that these substances can only have an effect in all other chorioretinal disorders involving a vascular component.

20        The invention is not limited to the use of ramipril and ramiprilat for the treatment of the disorders mentioned above. Other angiotensin converting enzyme inhibitors can be substituted that can induce effects 1, 2 and 3 mentioned above, in doses that are sufficiently low not to affect the general pressure in persons to whom it will be administered to those ends, in particular if the inhibitors have respective inhibition and isomerisation reversibility reaction constants satisfying the criteria defined above.

The term "visual function" as used in the claims below should be understood to refer more particularly but not in a limiting manner to visual acuity or to the field of vision or, as is preferable, to both at once.

The invention thus concerns a neuroprotective and retinoprotective ophthalmologic drug that can interrupt the process of degradation of visual function and even reverse its course, characterized in that its active principle is constituted by an inhibitor for the enzyme converting angiotensin 1 to angiotensin 2 with a high degree of stability, and moreover the inhibitor simultaneously has:

- an equilibrium inhibition constant  $K_i$  that governs the in vitro inhibition of rabbit converting enzyme by the inhibitor, the constant being lower than that of enalaprilat (50 pmol/l); and
- a constant  $k_4$  for the reversible isomerisation of the enzyme-inhibitor complex formed, the constant being lower than that of the complex formed by enalaprilat and the converting enzyme ( $1.1 \times 10^{-4}$ )(S1) in a medium (50 mM/l Hepes, 300 mmol/l NaCl, 1 micromol/l  $ZnCl_2$ , pH 7.5), wherein the vasodilatory activity is manifest not only in the arteries but also in the veins.

Preferably, the drug of the invention is more lipophilic in nature than enalaprilat.

The invention also concerns a drug in which ramipril or ramiprilat is in the form of their pharmaceutically acceptable salts or any other derivative of ramiprilat that can liberate ramiprilat into the organism to which the active principle is administered.

## CLAIMS

1. A neuroprotective and retinoprotective ophtalmologic drug that can interrupt the process of degradation of visual function and even reverse its course, characterized in that its active principle is constituted by an inhibitor for the enzyme converting angiotensin I to angiotensin II, with a high degree of stability.
2. A drug according to claim 1, in which the inhibitor simultaneously exhibits:
  - an equilibrium inhibition constant  $K_i$  that governs the in vitro inhibition of rabbit converting enzyme by the inhibitor, the constant being lower than that of enalaprilat (50 pmol/l); and
  - a constant  $k_4$  for the reversible isomerisation of the enzyme-inhibitor complex formed, the constant being lower than that of the complex formed by enalaprilat and the converting enzyme ( $1.1 \times 10^{-4}$ )(S1) in a medium (50 mM/l Hepes, 300 mmol/l NaCl, 1 micromol/l  $ZnCl_2$ , pH 7.5), wherein the vasodilatory activity is manifest not only in the arteries, but also in the veins.
3. A drug according to claim 1 or claim 2, characterized in that the inhibitor is more lipophilic in nature than enalaprilat.
4. A drug according to any one of claims 1 to 3, characterized in that the active principle is ramipril, ramiprilat, one of their pharmaceutically acceptable salts or any other derivative of ramiprilat that can liberate ramiprilat into the organism to which the active principle is administered.
5. A drug according to any one of claims 1 to 4, characterized in that it is in the form of an eye lotion.
6. Use of a drug active principle as defined in any one of claims 1 to 4 for the manufacture of ophtalmologic neuroprotective or retinoprotective drugs that can interrupt the visual function degradation process and even reverse its course.

7. Use according to claim 6, in a method for manufacturing drugs for treating glaucomatous neuropathies.
8. Use according to claim 6, for the production of drugs for treating degenerative chorioretinopathies of severe myopia.
- 5 9. Use according to claim 6, for the production of drugs for treating age-related macular degeneration with or without sub-retinal neovessels.
10. Use according to claim 6, for the production of drugs for treating central serous chorioretinopathies and diffuse retinal epitheliopathies.
11. Use according to claim 6, for the production of drugs for treating hereditary dystrophies  
10 of the retina.
12. Use according to claim 6, for the production of drugs for treating retinal venous occlusions.
13. Use according to claim 6, for the production of drugs for improving the visual function (visual acuity and field of vision) of aged subjects.
- 15 14. Use according to any one of claims 6 to 13, for the production of drugs in the form of eye lotions.

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION  
EN MATIÈRE DE BREVETS (PCT)

(19) Organisation Mondiale de la Propriété  
Intellectuelle  
Bureau international



(43) Date de la publication internationale  
21 décembre 2000 (21.12.2000)

PCT

(10) Numéro de publication internationale  
**WO 00/76499 A3**

(51) Classification internationale des brevets:  
A61K 31/00, 31/403, 38/55, A61P 27/02

(21) Numéro de la demande internationale:  
PCT/FR00/01679

(22) Date de dépôt international: 16 juin 2000 (16.06.2000)

(25) Langue de dépôt: français

(26) Langue de publication: français

(30) Données relatives à la priorité:  
SN 99 122 16 juin 1999 (16.06.1999) TN  
99/15359 6 décembre 1999 (06.12.1999) FR

(71) Déposant (*pour tous les États désignés sauf US*): REKIK,  
Elyes, Ben, Mohamed, Raouf [TN/FR]; 5, avenue du  
Poitou, F-92330 Sceaux (FR).

(71) Déposant et

(72) Inventeur: REKIK, Raouf [TN/TN]; 3, avenue Louis  
Brailles, 1002 Tunis (TN).

(74) Mandataires: GUTMANN, Ernest etc.; Ernest Gutmann-  
Yves Plasseraud S.A., 3, rue Chauveau-Lagarde, F-75008  
Paris (FR).

(81) États désignés (*national*): AE, AG, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,  
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) États désignés (*régional*): brevet ARIPO (GH, GM, KE,  
LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), brevet eurasien  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Publiée:

— Avec rapport de recherche internationale.

(88) Date de publication du rapport de recherche  
internationale: 17 mai 2001

*En ce qui concerne les codes à deux lettres et autres abrévia-  
tions, se référer aux "Notes explicatives relatives aux codes et  
abréviations" figurant au début de chaque numéro ordinaire de  
la Gazette du PCT.*

(54) Title: NEUROPROTECTIVE AND RETINOPROTECTIVE OPHTHALMOLOGIC MEDICINES

(54) Titre: MÉDICAMENTS OPHTHALMOLOGIQUES NEURO-ET RETINO-PROTECTEURS

(57) Abstract: The invention concerns a neuroprotective and retinoprotective medicine, whereof the active principle is selected among a group of compounds consisting of ramipril, ramiprilate or any other ramiprilate derivative capable of releasing it in the organism where it is administered. Said medicine is used for prevention, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies involving a vascular factor, in particular glaucomatous neuropathy, degenerative choriopathy of strong myopia, age-related maculopathy, serous central chorioretinopathy, hereditary dystrophy of the retina and retinal venous occlusions. It almost invariably improves the visual function (acuity and visual field).

(57) Abrégé: L'invention concerne un médicament neuroprotecteur et rétinoprotecteur, dont le principe actif est choisi au sein d'un groupe de composés consistant en le ramipril, le ramiprilate ou tout autre dérivé du ramiprilate susceptible de le libérer dans l'organisme auquel il serait administré. Il est appliqué à la prévention, ou même l'amélioration de l'acuité visuelle et du champ visuel chez des sujets normaux, ainsi qu'au traitement de pathologies ophtalmiques mettant en jeu un facteur vasculaire, notamment de neuropathies glaucomateuses, de chorio-rétinopathies dégénératives du fort myope, des dégénérescences maculaires liées à l'âge, de chorio-rétinopathies séreuses centrales, de dystrophies héréditaires de la rétine et d'occlusions veineuses rétinienne. Il entraîne pratiquement toujours une amélioration de la fonction visuelle (acuité et champ visuel).

WO 00/76499 A3

**PATENT**  
**ATTORNEY DOCKET NO: 50062/006001**

**COMBINED DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NEUROPROTECTIVE AND RETINOPROTECTIVE OPHTHALMOLOGIC DRUGS, the specification of which

☐ is attached hereto.

☒ was filed on December 14, 2001 as Application Serial No. 10/018,235  
and was amended on \_\_\_\_\_.

☐ was described and claimed in PCT International Application No. \_\_\_\_\_  
filed on \_\_\_\_\_ and as amended under PCT Article 19 on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, § 1.56.

**FOREIGN PRIORITY RIGHTS:** I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?
PCT	PCT/FR00/01679	June 16, 2000	Yes
France	99/15359	December 16, 1999	Yes
Tunisia	SN 99 122	June 16, 1999	Yes

**PROVISIONAL PRIORITY RIGHTS:** I hereby claim priority benefits under Title 35, United States Code, § 119(e) and § 120 of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

Serial Number	Filing Date	Status

## COMBINED DECLARATION AND POWER OF ATTORNEY

**NON-PROVISIONAL PRIORITY RIGHTS:** I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Filing Date	Status

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Ph.D. Reg. No. 35,238, Kristina Bieker-Brady, Ph.D. Reg. No. 39,109, Susan M. Michaud, Ph.D. Reg. No. 42,885, James D. DeCamp, Ph.D., Reg. No. 43,580, Sean J. Edman, Reg. No. 42,506, Timothy J. Douros, Reg. No. 41,716.

Address all telephone calls to: Kristina Bieker-Brady, Ph.D. at 617/428-0200.

Address all correspondence to: Kristina Bieker-Brady, Ph.D. at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110. **Customer No: 21559**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Raouf Rekik	Tunis, Tunisia	3 avenue Louis Brailles 1002 Tunis Tunisia	Tunisia
Signature: <i>Raouf Rekik</i>			Date: 27.01.02

TNX